Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus
Launched by YUFAN WANG · Feb 9, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the diagnosis and treatment of diabetic retinopathy (DR), a serious eye condition that can affect people with type 2 diabetes. The researchers aim to create a model that helps identify DR early by looking at clinical indicators (like blood sugar levels) and features from eye images, as well as analyzing certain substances in the blood (metabolomics). They plan to develop a system that can provide tailored care based on when diabetes started and whether patients have other complications. Additionally, the study will explore how cloud-based tools and continuous glucose monitoring can enhance the management of patients who need surgery for advanced DR.
To participate in this trial, individuals must be between 20 and 79 years old and have been diagnosed with type 2 diabetes according to specific guidelines. They should also be mentally capable and willing to take part in the study by signing a consent form. However, those with type 1 diabetes, severe health issues, or who are pregnant or breastfeeding are not eligible. If you join this study, you’ll be part of a groundbreaking effort to improve care for people with diabetic retinopathy, helping to manage this condition more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets the diagnostic criteria for type 2 diabetes in the "China Type 2 Diabetes Prevention and Treatment Guidelines (2020 Edition)";
- • Aged between 20 and 79 years old, without other severe underlying diseases; ③ Possesses full cognitive and literacy abilities; ④ Volunteers to participate in this study and are willing to sign an informed consent form.
- Exclusion Criteria:
- • Those who have been diagnosed with type 1 or other types of diabetes;
- • Those with severe cardiac, pulmonary, hepatic, or renal insufficiency;
- • Those with mental confusion, speech disorders, or dementia, etc.;
- • Those who are unable to take care of themselves, bedridden, or have mobility impairments; ⑤ Women who are breastfeeding or pregnant;
- • Those with a recent history of surgery, trauma, acute major vascular complications, or infectious diseases.
About Yufan Wang
Yufan Wang is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous methodologies. With a strong focus on collaboration and ethical practices, Yufan Wang aims to facilitate the development of novel therapies across various therapeutic areas. The organization prioritizes patient safety and data integrity, ensuring that all trials adhere to the highest regulatory standards. Through strategic partnerships and a patient-centric approach, Yufan Wang strives to contribute to the advancement of healthcare and the discovery of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lanzhou, , China
Shanghai, , China
Shenyang, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported